Non-Invasive Prenatal Testing (NIPT) Market is estimated to be 11.8 Billion by 2029 with a CAGR of 11.9% during the forecasted period.


A Non-Invasive Prenatal Testing (NIPT) is a screening test to identify if the unborn child/fetus is at risk for a number of genetic disorders like Down syndrome, Edwards syndrome, Patau syndrome, etc. The test is done by using blood sample thus reducing the risk of miscarriage during testing to absolute nil coupled with the ability to screen for a number of disorders within 10 weeks in pregnancy, much earlier as compared to any other prenatal diagnostic tests. NIPT has been ranked as the most successful, sensitive and the most accurate test thereby being the mostly preferred test. The global non-invasive prenatal testing (NIPT) market accounted for US$ 4.3  billion in 2019 and is estimated to be US$ 11.8 billion by 2029 and is anticipated to register a CAGR of 11.9%.

The report "Global Non-Invasive Prenatal Testing (NIPT) Market, By Product Type (Devices, Consumables, and Others), By Techniques (cfDNA, Biochemical Screening Tests, and Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, and Others), By End-User (Diagnostic Laboratories, Hospitals, and Cell DNA screening), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

  • In April 2017, Illumina, Inc. introduced VeriSeq NIPT solution in Europe (CE marked), which is useful for screening Trisomy (Down’s syndrome, Sex Chromosome Disorders, Microdeletion Syndrome).
  • In January 2017, Agilent Technology acquired Multiplicom N.V. (Belgium) in order to create comprehensive offerings for next-generation sequencing solutions.
  • In January 2019, Yourgene Health plc (U.K.) launched the Sage 32 plex test which uses Thermo Fisher’sIon Torrent sequencing technology to detect placental cff-DNA in a maternal blood sample.

Analyst View:

Maternal age plays an important role in the health of the child and delay in the maternal age can lead to various risk such as decreased fertility, high blood pressure, and an increase in the risk of miscarriage, stillbirths, and maternal death. Moreover, advancing maternal age can increase the risk of genetic disorders in babies as a result of the improper chromosomal division. The resulting abnormalities in babies may include microcephaly; short neck; upward slanted eyes; poor muscle tone; and heart, intestine, and breathing problems. In order to detect genetic abnormalities resulting from improper chromosomal division, there is a growing demand for early screening in expecting mothers. Therefore, Non-invasive prenatal testing being the safest one is boosting the market.

Key Market Insights from the report:        

The global non-invasive prenatal testing (NIPT) market accounted for US$ 4.3 billion in 2020 and is estimated to be US$ 11.8 billion by 2029 and is anticipated to register a CAGR of 11.9%. The market report has been segmented on the basis of product type, technique, application, end-user and region.

  • Depending uponproduct type, consumables segment dominated the overall NIPT market. The growth of this segment is mainly because of the increasing incidences of chromosomal abnormalities, rise in the number of tests and products for NIPT, and improvement of approvals or licenses for assays.
  • In terms oftechnique, the cfDNA segment is expected to show the highest CAGR during the forecast period due to technological advancements and increasing company initiatives to develop new products.
  • By application, trisomy segment dominates the market due to the increasing maternal age and the rising incidence of chromosomal abnormalities.
  • Based on the end user, diagnostic laboratories are estimated to have the highest revenue share due to the implementation of initiatives by diagnostic laboratories to provide safe and effective prenatal tests and rising incidence of chromosomal abnormalities.
  • By region,North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The reason being the developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in these regions.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4519

Competitive Landscape:

The prominent player operating in the global non-invasive prenatal testing (NIPT) market accounted includes Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, Laboratory Corporation of America Holdings, Yourgene Health, and Berry Genomics.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Comments

Post a Comment

Popular posts from this blog

Global Platelet Rich Plasma Market is estimated to be US$ 1003.06 million by 2030 with a CAGR of 11.50% during the forecast period.

Image
Global Platelet Rich Plasma Market accounted for US$ 337.23 million in 2020 and is estimated to be US$ 1003.06 million by 2030 and is anticipated to register a CAGR of 11.50%. Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is created by extracting red blood cells from blood. When the concentration of platelets in human blood is reduced, platelet-rich plasma is separated, which contains a concentration of platelets above typical values. Platelets thicken the blood and aid in the repair of muscles, ligaments, and tendons. They are extremely high in healing and connective tissue development factors. Platelet-rich plasma (PRP) blends the body's natural ability to heal itself with modern technologies. It has a wide range of medical applications, including neurology, orthopaedics, and ophthalmology. It's also employed in procedures like tendon repair and rotator cuff augmentation. The report   " Global Platelet Rich Plasma Market, By Type (Pure Platelet...
Read more

Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market

Image
Neurodegenerative Disorder Therapeutics Market   accounted for US$ 9.32 billion in 2019 and is estimated to be US$ 21.3 billion by 2029 and is anticipated to register a CAGR of 8.7% The report " Global  Neurodegenerative Disorder Therapeutics Market, By  Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In November 2019, Alkermes plc and Rodin Therapeutics, Inc. announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused ...
Read more

Systemic Lupus Erythematosus Market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%

Image
  Systemic Lupus Erythematosus (SLE) is the chronic, autoimmune disorder which involves several organ-systems such as kidney, heart, blood, skin, joints, and lungs in most severe cases, brain. In this disease, the human immune system converts hyperactive and attacks the healthy, normal tissues of the body. SLE can often result in symptoms such as malar rash, sub-acute cutaneous lesions, discoid lesions, arthritis, photosensitivity, oral ulcers, serositis, nephropathy, thrombocytopenia, haemolytic anemia, neurologic involvement, fever, thrombosis, Raynaud’s phenomenon, livedo reticularis, and myositis. The global systemic lupus erythematosus market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%. The report  " Global   Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics), By Route of Administration (Oral, In...
Read more